TRIAL | POPULATION STUDIED | AGE RANGE (MEAN), Y | TARGET SBP, MM HG | ACHIEVED MEAN BP, MM HG | PRIMARY OUTCOME AND COMMENTS |
---|---|---|---|---|---|
JATOS1 (N = 2418) | Japanese patients with SBP ≥ 160 mm Hg | 65–85 (74) | Treatment: < 140 Control: 140–159 | 136/75 vs 146/78 |
|
VALISH2 (N = 3260) | Japanese patients with ISH (SBP 160–199 mm Hg) | 70–84 (76) | Treatment: < 140 Control: 140–149 | 137/75 vs 142/77 |
|
ACCORD-BP3 (N = 4733) | Patients with T2DM with high risk of CV disease | 40–79 (62) | Treatment: < 120 Control: < 140 | 119.3 vs 133.5 |
|
ACCORD-BP—Action to Control Cardiovascular Risk in Diabetes–Blood Pressure, ARB—angiotensin receptor blocker, BP—blood pressure, CCB—calcium channel blocker, CV—cardiovascular, ISH—isolated systolic hypertension, JATOS—Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients, SBP—systolic blood pressure, T2DM—type 2 diabetes mellitus, VALISH—Valsartan in Elderly Isolated Systolic Hypertension.